James Meyers

Mr. Meyers joined the Arbutus board of directors in October 2018. He also serves as a Board Member for CytomX Therapeutics and Sangamo Therapeutics. Mr. Meyers has served as a Senior Advisor to Gilead Sciences since his retirement from Gilead Sciences in February 2018. In his 22 years at Gilead, Mr. Meyers was one of a relatively small group of executives who were instrumental in transitioning the company from an innovative start-up to one of the most successful biopharmaceutical organizations in the world. Prior to his advisory role, Mr. Meyers served as Gilead’s Executive Vice President of Worldwide Commercial Operations (Chief Commercial Officer), responsible for all commercial activities including pricing and market access. Mr. Meyers also led some of the most important and successful product launches in the history of the biopharmaceutical industry, most notably in the therapeutic areas of HCV and HIV. Prior to Gilead, Mr. Meyers served in roles of increasing responsibility at both Zeneca Pharmaceuticals and Astra U.S.A. He received his Bachelor’s degree in Economics from Boston College.